MetaVia (MTVA) Profit After Tax (2015 - 2026)
MetaVia's (MTVA) quarterly Profit After Tax came in at -$1.9 million in Q4 2025, up 62.69% YoY from -$1.2 million in Q4 2024, and up 42.85% on a QoQ basis from -$3.4 million in Q3 2025.
MetaVia (MTVA) Profit After Tax (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 11 years of Profit After Tax data on file, last reported at -$1.9 million in Q4 2025.
- Quarterly Profit After Tax rose 62.69% year-over-year to -$1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$13.0 million (up 52.98% YoY) and the FY2025 annual result came in at -$13.0 million, up 52.98% from the prior year.
- Profit After Tax rose to -$1.9 million in Q4 2025, from -$3.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$734000.0 in Q2 2023 to a low of -$10.1 million in Q2 2024.
- A 5-year average of -$4.1 million and a median of -$3.7 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2021 — Profit After Tax slumped 26715.38% — and 2023, when it jumped 77.78%.
- Tracing MTVA's Profit After Tax over 5 years: stood at -$4.6 million in 2021, then slipped by 2.36% to -$4.7 million in 2022, then retreated by 13.64% to -$5.3 million in 2023, then rose by 2.65% to -$5.2 million in 2024, then soared by 62.69% to -$1.9 million in 2025.
- The last three Profit After Tax figures came in at -$1.9 million (Q4 2025), -$3.4 million (Q3 2025), and -$4.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | -5.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.32 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Sep 30, 2025 | -3.38 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Mar 31, 2025 | -3.67 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -5.65 Mn |
| Jun 30, 2024 | -10.05 Mn |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | -5.31 Mn |
| Sep 30, 2023 | -3.82 Mn |
| Jun 30, 2023 | -734,000.00 |
| Mar 31, 2023 | -2.60 Mn |
| Dec 31, 2022 | -4.68 Mn |
| Sep 30, 2022 | -3.10 Mn |
| Jun 30, 2022 | -3.30 Mn |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -4.57 Mn |
| Sep 30, 2021 | -3.46 Mn |
| Jun 30, 2021 | -3.92 Mn |